Dendritic cell vaccine (Head and neck tumor), National Cancer Institute

N/A

Report date: 2023/03/16 13:29:49

Base Information

Drug NameDendritic cell vaccine (Head and neck tumor), National Cancer Institute

Drug Alias Namemutant p53 peptide pulsed dendritic cell vaccine树突状细胞疫苗-美国国立癌症研究所Dendritic cell vaccine(National Health Research Institutes)

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionTumor protein p53 modulators

TargetsTumor protein p53

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesNational Health Research Institutes

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A